

11/09/2023

Change in Preferred Drug List Status for the Macrolides-Ketolides Drug Class Effective Nov. 7, 2023

Background:

HHSC is aware of a drug shortage for the brand name Eryped 200 MG/5 ML suspension in the Macrolides-Ketolides drug class.

Key Details:

In response to the shortage of the preferred brand name product Eryped 200 MG/5 ML suspension, HHSC removed the non-preferred status from the generic erythromycin 200 MG/5 ML and E.E.S. 200 MG/5 ML suspension on the preferred drug list (PDL). The preferred status of the brand name Eryped 200 MG/5 ML suspension (NDC 24338013213) will not change to allow for any existing stock available to be utilized. HHSC removed the non-preferred status for the drugs on the attached file, effective Nov. 7, and HHSC will reflect these changes in the daily formulary file on Nov. 8.

These changes will allow providers to prescribe the generic erythromycin 200 MG/5 ML and E. E.S. 200 MG/5 ML suspension without requiring a PDL prior authorization and continue accessing necessary medication for clients.

| The table below lists the erythromycin products with their NDCs. | |
|---|-------------------------------|
| NDC | Generic Drug Name |
| 62559044001 | ERYTHROMYCIN 200 MG/5 ML SUSP |
| 62559044002 | ERYTHROMYCIN 200 MG/5 ML SUSP |
| 62559063001 | ERYTHROMYCIN 200 MG/5 ML SUSP |
| 69238150301 | ERYTHROMYCIN 200 MG/5 ML SUSP |
| 75834029501 | ERYTHROMYCIN 200 MG/5 ML SUSP |
| 24338013402 | E.E.S. 200 MG/5 ML SUSPENSION |
| 24338013610 | E.E.S. 200 MG/5 ML SUSPENSION |

Email vdp-formulary@hhsc.state.tx.us with comments or questions.

Source: <https://www.tmhp.com/news/2023-11-10-change-pdl-status-macrolides-ketolides-drug-class-effective-november-7-2023>